Lightchain Capital

Recent News

Logo-Geneoscopy-400
November 09, 2023

Noninvasive Multitarget Stool RNA Test Proves Sensitive for Colorectal Cancer, Advanced Adenomas

READ MORE
Logo-Geneoscopy-400
November 09, 2023

Don Hardison Appointed Chairman of the Board at Geneoscopy

READ MORE
wugen-logo-400
November 02, 2023

Wugen to Present New Clinical Data for WU-CART-007 and Preclinical Data for WU-NK-101, Two Investigational Allogeneic Cell Therapies for Challenging Hematologic Cancers, at American Society of Hematology Annual Meeting & Exposition

READ MORE
Logo-Geneoscopy-400
October 23, 2023

JAMA Publishes Geneoscopy’s Pivotal CRC-PREVENT Trial Results, Reporting Highest Sensitivity for Detecting Colorectal Cancer and Advanced Adenomas Among Available Noninvasive Screening Tests

READ MORE
Logo-Geneoscopy-400
October 05, 2023

Geneoscopy to Present and Exhibit at American College of Gastroenterology 2023 Annual Meeting

READ MORE
aiProteins_Final_logo300
October 04, 2023

AI Proteins Announces the Appointment of Dr. Robert Stein to its Scientific Advisory Board

READ MORE
CareVet-Logo-New
September 26, 2023

CareVet Partners with Blendvet™ & Hill’s Pet Nutrition to Launch Groundbreaking DEIB Initiative

READ MORE
NextRNA-Logo-FullColor-400
September 26, 2023

NextRNA Therapeutics Strengthens Board of Directors with Appointment of Lori Friedman, PhD

READ MORE
wugen-logo-400
September 09, 2023

Wugen Presents Initial Data from First-in-Human Phase 1/2 Trial of WU-CART-007 at the European Hematology Association (EHA) 2023 Congress

READ MORE
Logo-Geneoscopy-400
September 06, 2023

Geneoscopy CEO Andrew Barnell to Present at the Morgan Stanley 21st Annual Global Healthcare Conference

READ MORE

Contact Us

Lightchain Capital, LLC
PO Box 31729
St. Louis, MO 63131

 

LinkedIn

Submit

©2021 LIGHTCHAIN CAPITAL, LLC  All Rights Reserved | Privacy Policy
Website by Tidal Media Group